- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04871282
A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Johnathan Yovell, MD
- Phone Number: +972-8-3731535
- Email: clinicaltrials@ayalapharma.com
Study Contact Backup
- Name: Yelena Lalazar, RN, MPH
- Phone Number: +972-8-3731535
- Email: clinicaltrials@ayalapharma.com
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Chris O'Brien Lifehouse
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Adelaide Cancer Centre
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
-
Gent, Belgium, 9000
- Universitair Ziekenhuis
-
Leuven, Belgium
- Universitaire Ziekenhuizen Leuven
-
-
-
-
-
Berlin, Germany, 13125
- Helios Klinikum Berlin-Buch
-
Mannheim, Germany, 68167
- Mannheim university medical center
-
-
-
-
-
Ashkelon, Israel
- Oncology Institute Barzilai Medical Center
-
Haifa, Israel, 3109601
- Rambam MC
-
Jerusalem, Israel, 9112001
- Hadassah University Hospital - Ein Kerem
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, Italy, 40136
- IRCCS Istituto Ortopedico Rizzoli
-
Milano, Italy, 20133
- IRCCS Fondazione Istituto Nazionale dei Tumori
-
Rome, Italy, 00128
- Campus Bio-Medico University Hospital
-
-
-
-
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 43-gil
- Asan Medical Center
-
-
-
-
-
Amsterdam, Netherlands, 1066CX
- The Netherlands Cancer Institute
-
Leiden, Netherlands
- Leiden University Medical Center
-
Rotterdam, Netherlands, 3015 AA
- Erasmus Medisch Centrum
-
-
-
-
-
Warsaw, Poland, 00-001
- Maria Sklodowska-Curie National Research Institute of Oncology
-
-
-
-
-
Barcelona, Spain, 08035
- Vall d´Hebrón University Hospital
-
Barcelona, Spain, 08908
- Catalan Institute of Oncology (ICO)
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jiménez Díaz
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Zaragoza, Spain, 50009
- Hospital Universitario Miguel Servet
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital
-
London, United Kingdom, SW3 6JJ
- The Royal Marsden Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie NHS Foundation Trust
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH4 2XU
- Western General Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Research Center
-
Santa Monica, California, United States, 90404
- University of California at Los Angeles Hematology/Oncology
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- NorthShore University Health System
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02214
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Missouri
-
Jefferson City, Missouri, United States, 65109
- Jefferson City Medical Group
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Columbus, Ohio, United States, 43210
- Ohio State University Wexner Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson University Hospital
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center, Hillman Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75235
- UTSW Simmons Cancer Center
-
Houston, Texas, United States, 77005
- MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria Part A:
- At least 18 years of age (inclusive) at the time of signing the ICF.
- Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent).
Disease progression, assessed locally by the investigator, defined as having at least one of the following:
- Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI
- Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication
- At least 1 measurable lesion amenable to volume measurements by MRI at screening (Part A only)
One of the following:
- Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR
- Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)
- Agrees to provide formalin-fixed paraffin embedded archival or fresh tumor tissue for re- confirmation of disease.
- Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.
Exclusion Criteria Part A:
- Diagnosed with a malignancy in the past 2 years with some exceptions.
- Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn's disease.
- Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti- fungal therapy ≤7 days prior to administration of IP such as known active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at Screening.
- Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has New York Heart Association (NYHA) Class III or IV heart failure, , symptomatic ventricular arrhythmias, sustained ventricular tachycardia, Torsade's de Pointes (TdP), the long QT syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia.
- Unstable or severe uncontrolled medical condition (e.g., unstable cardiac or pulmonary function or uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the subject associated with his or her participation in the study.
- Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.
- Eastern Cooperative Oncology Group (ECOG) performance status ≥2
Abnormal organ and marrow function at Screening defined as:
- Neutrophils <1000/mm3,
- Platelet count <100,000/mm3,
- Hemoglobin <9 g/dL,
- Total bilirubin >1.5x upper limit of normal (ULN) (except known Gilbert's syndrome),
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x ULN,
- Serum creatinine > ULN and creatinine clearance (CrCl) <60 mL/min (calculation of CrCl will be based on acceptable institution standard)
- Uncontrolled triglyceride ≥Grade 2 elevations per common terminology criteria for adverse events (CTCAE) v5.0 (>300 mg/dL or >3.42 mmol/L).
ECG Exclusions (Part A only)
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.
- QRS duration > 110 ms
- PR interval > 240 ms
- Marked ST-T wave abnormalities which would make it difficult to measure the QT interval
Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to < CTCAE Grade 2 or clinical baseline. Therapy includes:
- Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery
- Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy
- Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP;
Inclusion Criteria Part B
- ≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.
- Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.
- Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.
- Subject and/or legally authorized representative (i.e. parent/guardian) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.
- Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).
For all other inclusion criteria refer to Part A inclusion criteria.
Exclusion Criteria Part B The subjects must be excluded from participating in the study if they meet any of the exclusion criteria for Part A, except where otherwise noted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A Main Study 1.2 mg daily
AL102 1.2 mg
|
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
|
Experimental: Part A Main Study 2 mg Intermittent
AL102 2 mg
|
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
|
Experimental: Part A Main Study 4 mg Intermittent
AL102 4 mg
|
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
|
Experimental: Part B AL102
AL102, recommended dose regimen from Part A, 1.2 mg daily
|
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
|
Placebo Comparator: Part B Placebo
Placebo to match recommended dose regimen from Part A
|
Placebo to match AL102
|
Experimental: Open Label Extension
AL102, recommended dose regimen from Part A, 1.2 mg daily
|
AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: Approximately 2 years
|
Progression free survival (PFS) as defined as the time from randomization until the date of assessment of progression (as assessed by BICR based on RECIST v1.1) or death by any cause
|
Approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: Approximately 2 years
|
Overall response rate (ORR) defined as the proportion of subjects with ORR (CR and PR) by BICR based on RECIST v1.1.
|
Approximately 2 years
|
Duration of response
Time Frame: Approximately 2 years
|
Duration of response defined by the time from CR or PR (by BICR based on RECIST v1.1) until the earlier of the first documentation of disease progression or death from any cause.
|
Approximately 2 years
|
Patient reported outcome
Time Frame: Approximately 2 years
|
Change from baseline in quality of life as measured by GOunder/Desmoid Tumor Research Foundation (DTRF) DEsmoid Symptom Scale and Impact Scale (GODDESS)
|
Approximately 2 years
|
Patient reported outcome
Time Frame: Approximately 2 years
|
Change from baseline in quality of life as measured by Patient-reported outcomes measurement information system (PROMIS) Physical Function
|
Approximately 2 years
|
Patient reported outcome
Time Frame: Approximately 2 years
|
Change from baseline in quality of life as measured by EuroQol 5-dimensional questionnaire(EQ-5D)
|
Approximately 2 years
|
Patient reported outcome
Time Frame: Approximately 2 years
|
Change from baseline in pain assessment using brief pain inventory (BPI) short form
|
Approximately 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mrinal Gounder, MD, MSKCC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AL-DES-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Desmoid Tumor
-
Rabin Medical CenterCompletedDesmoid Fibromatosis | Desmoid | Desmoid Fibromatosis of Skin | Desmoid Neoplasm of Chest Wall | Desmoid Tumor Caused by Somatic Mutation | Aggressive Fibromatoses | Fibromatosis DesmoidIsrael
-
Italian Sarcoma GroupCompletedAdvanced Desmoid Tumor | Advanced ChondrosarcomaItaly
-
Blokhin's Russian Cancer Research CenterNot yet recruitingDesmoid Fibromatosis | Desmoid Tumor | DesmoidRussian Federation
-
University of Colorado, DenverSpringWorks Therapeutics, Inc.No longer availableNeoplasm | Desmoid TumorUnited States
-
Erasmus Medical CenterRadboud University Medical Center; Royal Marsden NHS Foundation Trust; The Netherlands...CompletedDesmoid Tumor | Desmoid-type FibromatosisUnited Kingdom, Netherlands
-
Technische Universität DresdenUniversitätsmedizin Mannheim; SOS Desmoid e.V.RecruitingQuality of Life | Desmoid TumorGermany
-
University Hospital, Strasbourg, FranceRecruiting
-
MaineHealthPfizer; Desmoid Tumor Research FoundationCompleted
-
University Hospital, Strasbourg, FranceCompleted